Purpose: This study was undertaken to estimate the incidence of retinal changes and determine the pre valence of ocular toxicity associated with tamoxifen treatment in a breast cancer population.
• st 3 years of treatment or in patients receiving a total _oxifen dosage of less than 23.7 g. Although retinopathy can occur in a tamoxifen-treated popula lion, its low incidence and an associated good prognosis for vision does not merit special screening for this problem.
Tamoxifen (Nolvadex), a non-steroidal oestrogen antagonist, has proved to be an effective adjuvant hormonal therapy in the treatment of breast cancer. 1 This triphenylethylene derivative exerts its anti oestrogenic properties by competitively binding to cytoplasmic oestrogen receptors, thus arresting the cell in G 1 phase. 
RESULTS
Crystalline deposits in the posterior pole consistent with previously described tamoxifen retinopathy were found in 3 patients (0.9%) ( Table I) . No other ocular abnormalities were evident, and visual acuity was not affected in any of the 3 patients. The length of tamoxifen treatment in these 3 patients ranged from 39 months to 120 months, and the total dosage of tamoxifen ranged from 23.7 g to 73 g ( Table II ). All 3 patients with retinal changes were found in the Oklahoma City group, which had the longest mean duration of treatment (55 months) and the highest total dosage of tamoxifen (72 g).
DISCUSSION
Tamoxifen has proved to be beneficial in the Tamoxifen is remarkably well tolerated, with fewer than 3% of patients withdrawing from clinical trials. Although most of the toxicity is related to the anti-oestrogenic properties of the drug, ocular Table II . Clinical factors associated with retinal changes toxicity has also been reported -specifically a tamoxifen-induced retinopathy.
A review of tamoxifen-induced retinopathy reported in the literature is shown in Table III .
Retinopathy is a rare occurrence in patients receiving
20 mg daily of tamoxifen; in our study it was not associated with changes in visual acuity or visual function. We found no evidence of tamoxifen retinopathy during the first 3 years of treatment or with a total dosage of less than 23. 
